What is HC Wainwright’s Forecast for TPST FY2025 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities researchers at HC Wainwright lifted their FY2025 earnings estimates for Tempest Therapeutics in a report released on Thursday, January 22nd. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($6.10) for the year, up from their previous forecast of ($12.78). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2025 earnings at ($0.62) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($2.13) EPS.

Several other research analysts also recently weighed in on TPST. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Trading Up 1.4%

Tempest Therapeutics stock opened at $2.94 on Monday. The stock’s 50 day simple moving average is $3.05 and its two-hundred day simple moving average is $7.19. Tempest Therapeutics has a 12 month low of $2.40 and a 12 month high of $12.61. The firm has a market cap of $14.49 million, a PE ratio of -0.29 and a beta of -2.43.

Shares of Tempest Therapeutics are scheduled to split before the market opens on Friday, January 30th. The 2-1 split was recently announced. The newly created shares will be distributed to shareholders after the closing bell on Thursday, January 29th.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.27) by $2.48.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. increased its position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 162,560 shares of the company’s stock after acquiring an additional 27,952 shares during the quarter. Vanguard Group Inc. owned approximately 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the SEC. 22.52% of the stock is owned by institutional investors and hedge funds.

About Tempest Therapeutics

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.